PE-conjugated Anti-SN38 antibody(1G1); Rabbit mAb

SN38, a potent chemotherapeutic derived from irinotecan, plays a pivotal role in colorectal cancer treatment. As the active form of irinotecan, SN38 operates as an effective DNA topoisomerase I inhibitor, inducing cell death in cancer cells. Notably, SN38's potential is harnessed in Antibody-Drug Conjugates (ADCs), where it is delivered to tumor sites through innovative methods like liposomes and nanoparticles. This targeted approach enhances SN38's efficacy, emphasizing its crucial role in ADC-based strategies for precise and potent colorectal cancer therapy.